Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Ironwood Pharmaceuticals, based in Cambridge, Mass., has licensed to Spain's Laboratorios Almirall the European rights to develop and commercialize linaclotide, its investigational compound for irritable bowel syndrome. Almirall will pay $40 million up front plus potential precommercial licensing and milestone payments of up to $95 million. Ironwood would also receive royalties on sales in Europe.
This article has been sent to the following recipient: